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By 2020 one in five people in the UK will be aged over 65 years; life expectancy at birth is
increasing at the rate of three years every decade. Whether the extra years are spent
healthy and independent is still unknown but is of critical interest to the government and
to health and social care providers, as well as to older people themselves. The planning of
preventive, primary and secondary health services and social and long-term care services
for older people requires accurate projections of future need based on reliable estimates
of the prevalence and incidence of disability and an understanding of the impact of
chronic disease on function.
Using data from the Medical Research Council Cognitive Function and Ageing Study (MRC
CFAS) – a nationally representative sample of people aged 65 years and over – we have
explored the effect of different health scenarios on the future numbers of older people with
disability at a level that needs social care. From a review of four diseases – dementia,
stroke, coronary heart disease (CHD) and arthritis – we have developed evidence-based
scenarios for the health of the future older population. 
Our results show that ageing of the population alone, with no alteration in the prevalence
of diseases or the age-specific rates of becoming disabled or recovering, will result in a 67
per cent increase in the numbers with disability over the next 20 years. Numbers of the
oldest old (those aged 85 years and over) with disability will have doubled and the
numbers experiencing one of the key diseases considered will have increased by over 40
per cent by 2025. 
If the emphasis of public health interventions and medical treatments continues to be on
extending life at older ages, with little or no consideration for alleviating or postponing the
disabling consequences of disease, there will be around 50,000 more older people with
disability at a level that needs care by 2025, in addition to the rises resulting from the
ageing of the population. 
Moderate improvements in population health, from reductions in levels of obesity and
other negative health behaviours, and control of vascular risk factors, together with new
treatments or technologies focused on reducing the disabling consequences of disease,
could considerably reduce the numbers with disability by 2025, with up to 80,000 fewer
disabled older people. However, this would make only limited inroads into offsetting
population ageing and the numbers of disabled older people would still increase by 57 per
cent. It thus seems unlikely that a compression of disability will occur unless the severity
of disability associated with diseases diminishes.
We discuss these results in the light of findings from other countries and make
recommendations on the data needed to improve future projections.
Executive summary
vi COMPRESSION OR EXPANSION OF DISABILITY?
Life expectancy at birth has been increasing by three years every decade for over 100 years
with little evidence of the rate slowing down. Attention is now focusing more on the quality
of these extra years gained, particularly in terms of healthy active life, which older people
themselves view as important in addition to its central role in health and social care use. 
Theoretically, there have been three main scenarios for health accompanying the
extension in life expectancy: compression of morbidity (Fries 1980), where the onset of
chronic ill-health is postponed to a time closer to death; expansion of morbidity (Kramer
1980), where the years gained are through those in poor health being kept alive; and
dynamic equilibrium (Manton 1982), where the years gained may be with disability or ill-
health but the disability is less severe. At present, in the UK it remains unclear whether the
extra years of life lived are in good (compression of morbidity) or poor health (the
expansion of morbidity). Within the USA the picture appears much clearer, with most
studies now confirming that disability is being compressed into a shorter period of time
(Crimmins 2004).
Disability is not necessarily a consequence of ageing. Conceptual models of the
disablement process (Verbrugge and Jette 1994) place active pathology or disease at the
start of the process. Major causes of disability in later life are known to be the
consequences of both acute and chronic diseases and conditions such as cardiovascular
and cerebrovascular disease, sensory problems (vision and hearing), arthritis,
incontinence, dementia and depression (Stuck et al 1999). 
Demand on health and social care is strongly linked to disability levels but projections of
future need for long-term care have generally begun with disability and assumed that
overall prevalence will increase only as a result of the ageing of the population. Falling
mortality rates from cardiovascular diseases and the higher incidence of diabetes and
cardiovascular disease, in part caused by rising obesity levels, suggest that the
assumption of constant age- and sex-specific prevalence rates of disability may not be
tenable, particularly in the longer term. 
Most simulation models of population health have been concerned only with the
consequences for health care costs of changing risk factors and/or treatments and
interventions on mortality (Gunning-Schepers 1989; Wolfson 1994) or on the course of a
single disease process, for instance dementia (Brookmeyer et al 1998; Sloane et al 2002).
One other simulation model has linked disease and disability in later life (Boult et al
1994), although it considered only the effect of a global decrease in the prevalence of
diseases of 1 per cent (Boult et al 1996).
In our earlier work we began to develop a simulation model (SIMPOP) to project the
number of older people with disability under different disease scenarios in a similar
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Introduction
manner to an earlier American model (Boult et al 1996). The transition phase of this model
quantified the effect of acute and chronic diseases on mortality and the onset of disability
(Spiers et al 2005) using the Medical Research Council Cognitive Function and Ageing
Study (MRC CFAS 1998), a large nationally representative longitudinal study. 
It is against this background that the current work was commissioned in order to inform
how changing disease patterns might influence disability and therefore the need for care
in the future (within this report when we refer to care we mean social care services). This is
to ensure consistency with the Personal Social Services Research Unit (PSSRU) expenditure
model into which the disability projections feed. More explicitly this addresses the first of
the terms of reference for the Wanless Social Care Review – namely ‘to examine the
demographic, economic, social, health, and other relevant trends over the next 20 years
that are likely to affect the demand for and nature of social care for older people (aged 65
and over) in England’. The terms of reference for this paper are shown in the box below.
Approach
We confined ourselves to a few specific disease areas: stroke and coronary heart disease
(CHD), cognitive impairment and dementia, and arthritis. Our previous work suggested
that these encompassed a range of relationships with mortality and disability (for
example, arthritis has little impact on mortality whereas stroke and to a lesser degree
cognitive impairment both have strong relationships with mortality) and had different
albeit some joint risk factors (for example, obesity is a strong risk factor for arthritis,
stroke, CHD and vascular dementia).
The work took three stages.
 Stage 1 refined and tested the baseline simulation model with no changing disease
assumptions to ensure compatibility with the PSSRU model and with Government
Actuary Department (GAD) projections. In particular, the transition model linking
disease to disability onset and mortality was refitted with a definition of disability
compatible with the PSSRU model.
 Stage 2 comprised an extensive review of the evidence over the previous 15 years for
efficacy and diffusion of treatments (and in some cases service models) reducing
disability and/or mortality in each of the disease areas. From the reviews the team,
including three clinical experts, developed disease-specific scenarios as well as more
general scenarios involving all or most of the diseases. 
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TERMS OF REFERENCE
1. To review trends in disease and treatment in four areas: stroke, coronary heart
disease, dementia and cognitive impairment, and arthritis. 
2. To identify how disease patterns will impact on the future levels of disability of older
people over the next 20 years.
3. To produce disability prevalence rates within age groups over the next 20 years in a
form suitable to input to the PSSRU model of long-term care projections.
 In stage 3 we applied each of the scenarios in the simulation model to produce
numbers of older people with and without disability as well as age-specific disability
prevalence from 2001 to 2025. The prevalence rates were passed on to the PSSRU team
to input into the care expenditure mode (Malley et al 2006). 
The simulation model and literature review are presented in the second section. Fuller
details of the methodology of the simulation model and the complete literature reviews are
available from the authors (or accessed via www.hs.le.ac.uk/lnru/indexa/html). 
Structure of the report
The remainder of this report is structured as follows: 
 the second section describes the data and methodology for the transition and
simulation phases of the model
 the third section summarises the literature review of the disease areas that formed the
basis for the scenarios
 the fourth section describes the scenarios
 the fifth section presents the numbers of older people with and without disability over
the next 30 years under each of the scenarios
 the sixth and final section draws together the conclusions and provides
recommendations for the data required to inform future scenarios.
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Transition data
We used data from the Medical Research Council Cognitive Function and Ageing Study
(MRC CFAS) to model the effect of disease on disability onset and mortality. A full
description of the MRC CFAS study design can be found elsewhere (Gunning-Schepers
1989), but of relevance here is that the study was conducted in three urban (Newcastle,
Nottingham and Oxford) and two rural (Cambridgeshire and Gwynedd) centres within
England and Wales, including both community-dwelling and institutional residents aged
65 years and over, with those aged 75 years being over-sampled. At baseline, 13,004
people were interviewed. 
All participants were initially screened by trained interviewers in their current place of
residence during 1991–4, using a structured interview. The interview included questions
on sociodemographics, general health (including chronic conditions), cognition, smoking,
and basic and instrumental activities of daily living (ADLs/IADLs). Surviving participants
were interviewed again two years later, about their health and ADL status. MRC CFAS
version 7.1 was used for analysis. 
Disability measure
The MRC CFAS interviews included items from the modified Townsend activities of daily
living scale (Isaacs and Neville 1976), covering the participant’s ability to perform nine
activities and tasks, including eight ADLs/IADLs. Response categories were ‘Yes, with no
difficulty’, ‘Yes, with some difficulty’ and ‘No, needs help’. The participant’s mobility was
also rated by the interviewer as usually ambulant non-housebound, usually ambulant
housebound, chairfast permanently and bedfast permanently.
The threshold for disability was chosen to match, as closely as possible, to the definition
being used by the Personal Social Services Research Unit (PSSRU) – inability to perform at
least one ADL without help. Participants were therefore defined as having disability if they
were unable to put on shoes and socks, have a bath or all-over wash, or to transfer to and
from bed. This threshold gave a similar prevalence of disability by age and sex to the fifth
of the six disability groups used in the PSSRU model.
If answers to the first 10 questions in the interview, which addressed orientation, indicated
that the participant was disoriented in time or space, only a subset of questions was
asked. These participants (n = 235) were coded as disabled for the purposes of this model.
Simulation model
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Measures of disease 
At baseline, participants were asked if they had ever suffered from a heart attack, angina,
intermittent claudication, diabetes, asthma, chronic bronchitis, arthritis, Parkinson’s
disease, treated hypertension, stroke, emotional problems or underactive thyroid. Angina
and intermittent claudication (peripheral vascular disease) were elicited from the Rose
Scales (Rose et al 1977). 
Participants were considered to have coronary heart disease (CHD) if they reported having
suffered from a heart attack or angina, or were classified as having angina from the Rose
Angina Scale. Participants were classified as having had a stroke if they answered
positively to the question ‘Have you ever had a stroke that required medical attention?’
and also reported that the stroke was diagnosed by a GP or specialist. 
Cognitive impairment was assessed using the Mini-Mental State Examination (MMSE)
(Folstein et al 1975). Missing items were divided according to their nature. ‘Don’t know’,
‘No answer’ and items that could not be answered as a result of sensory or mobility
problems were recoded to zero. For all other items, the full score was recoded to missing,
unless the participant could be assigned to an MMSE category unambiguously on the
basis of the completed items.
Population data
The baseline UK population aged 65 years and over by two-year age bands were taken from
the 1991 Census in England and Wales of the Office for National Statistics. 
The new population aged 65–66 years at each two-year interval were obtained from three
sources. Population figures for 1992–2000 were taken from the 1991 population figures of
the Office for National Statistics, revised in light of the 2001 Census. Figures for the period
2001–2 were taken from the Government Actuary’s Department (GAD) 2000-based
principal projections, and for 2003 onwards from the GAD 2003-based principal
projections, including the 2001 Census revision. The 2003-based principal projections
assume improvements in mortality rates.
Transition phase
Of the 13,004 participants in the prevalence screen, 12,622 (97.1 per cent) provided
sufficient data for their functional status to be classified at baseline; 235 were classified as
disoriented after initial orientation questions and therefore classified as disabled at
baseline. 
A total of 1,366 participants were disabled at baseline, of whom 465 (34.0 per cent) died,
332 (24.3 per cent) were alive and disabled at follow-up and 140 (10.3 per cent) were alive
and not disabled at follow-up. Risk factors for improvement were not investigated because
of the small number with improved functional status and a relatively high loss to follow-up
(31.4 per cent, n = 429). 
Of the 11,491 participants not disabled at baseline, a total of 8,802 (76.6 per cent) were
successfully followed up for functional limitation at two years, of whom 7,389 (83.8 per
cent) were not disabled at two years, 472 (5.4 per cent) were disabled and 941 (10.7 per
cent) had died. 
SIMULATION MODEL 5
A trichotomous logistic regression model was fitted to estimate the effects of diseases on
the onset of disability and mortality in those not disabled at baseline, using STATA
Corporation (STATA 9.0, 4905 Lakeway Drive, College Station, TX 77485, USA). A small
number of participants (n = 113) were excluded from the transition model as a result of
missing covariates (chronic conditions or sociodemographics), so the model is presented
for 8,689 participants.
Projection phase
The simulation was programmed using SAS IML, and consists of two programs: BASEPOP,
which sets up the base population and initial quantities, and SIMPOP, which carries out
the dynamic simulation. The structures of BASEPOP and SIMPOP can be seen in Figure 1
above. 
Transition rates from disability were taken directly as observed from the transition rates
between the CFAS prevalence screen and the follow-up two years later.
Transition probabilities from no disability to disability and death are taken from the
transition model described earlier using the formulae in the box on p 8. 
We further adjusted both sets of transitions (from disability and no disability) to death for
every two-year period based on the GAD assumptions, because the GAD population
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STRUCTURE OF SIMULATION PROGRAMS, BASEPOP (BASE POPULATION AND INITIAL QUANTITIES), AND
SIMPOP (DYNAMIC SIMULATION)
1
BASEPOP: base quantities
(modules run once only)
BASEPOP runs once and
quantities stored in
module IMLlib within
SIMPOP program folder
MODULE B2
Inputs 1991
Census population
MODULE NEWB
Changes betas
MODULE NN2
Applies transition rates
MODULE NN3
Ages population
MODULE PREVD2
Calculates overall prevalence of
diseases
MODULE J2
Inputs betas from CFAS risk
factor model
MODULE G2
Inputs numbers aged 65 and 66
from 2003-based GAD projections
MODULE PC2
Inputs age-specific prevalence of
covariates in independent
population
MODULE DP2
Calculates disease prevalence in
dependent population
MODULE D2
Inputs CFAS transition probs
from dependence
MODULE A
Inputs age groups & CFAS
disability prevalence
MODULE MIND2
Calculates transition rates from
independence
MODULE PU2
Changes disease prevalence
MODULE MM
Sets start values & iteration
control
SIMPOP: iteration
1st iteration only
projections make assumptions that death rates will fall in the future. These adjustments
may be considered to encompass the impact of diseases that are not considered in the
model.
To calculate the numbers dying, becoming disabled and remaining without disability two
years later, the transition probabilities of onset and death are multiplied by the number of
functionally independent people in each group, in order. The 65- to 66-year age group at
each two-year interval are replenished assuming the same prevalence of disability as
estimated in MRC CFAS at 1991. 
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TABLE 1: TRICHOTOMOUS LOGISTIC REGRESSION MODEL OF SELF-REPORTED
DISEASES ASSOCIATED WITH ONSET OF DISABILITY AND DEATH IN THOSE FREE OF
DISABILITY AT BASELINE INTERVIEW IN MRC-CFAS (n = 8689)
Onset of disability Death
β (SE) β (SE)
Chronic conditions
Stroke 0.92 (0.17) 0.64 (0.14)
Peripheral vascular disease 0.21 (0.25) 0.19 (0.16)
Coronary heart disease (angina and heart attack) 0.26 (0.13) 0.56 (0.09)
Treated hypertension 0.13 (0.12) 0.19 (0.09)
Arthritis 0.50 (0.11) -0.04 (0.08)
Treated diabetes 0.38 (0.22) 0.51 (0.15)
Chronic airways obstruction 0.44 (0.13) 0.25 (0.10)
Parkinson’s disease 1.69 (0.35) 1.02 (0.35)
Hearing problems 0.06 (0.12) -0.002 (0.09)
Eyesight problems 0.64 (0.12) 0.06 (0.10)
MMSE1 22–25 0.53 (0.12) 0.65 (0.09)
0–21 0.96 (0.18) 1.55 (0.13)
Control variables
Age2 70–74 years 0.27 (0.19) 0.48 (0.13)
75–79 years 0.54 (0.18) 0.86 (0.12)
80–84 years 1.32 (0.18) 1.24 (0.13)
85+ years 1.75 (0.20) 1.89 (0.15)
Male sex -0.10 (0.12) 0.66 (0.09)
Living status3 Living with others 0.37 (0.16) 0.21 (0.12)
Living alone -0.02 (0.10) 0.11 (0.09)
Social class4 III 0.15 (0.12) 0.14 (0.09)
IV and V 0.27 (0.15) 0.27 (0.11)
Armed forces personnel/missing -0.40 (0.37) -0.32 (0.27)
Smoking5 Current smoker 0.02 (0.15) 0.38 (0.10)
1 versus MMSE 26–30
2 versus 65–69 years
3 versus living with spouse
4 versus social class I and II (I and II = professional and managerial or technical, III = manual and non-manual, 
IV and V = partly skilled and unskilled)
5 versus non-smoker
This process is run iteratively to simulate the future disabled population from 1991 to 2025.
Full details of the program and the adjustments to replicate the GAD projections are
available (see www.hs.le.ac.uk/nccsu). 
Comparison with GAD projections
Table 2 above shows that the numbers of people aged 65 years and over simulated using
the SIMPOP program, and assuming no change in prevalence or transition rates for any
disease, are comparable with those produced by the GAD projections.
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TRANSITION PROBABILITIES TO DISABILITY AND DEATH
P (onset of disability)= eβonsetX
1 + eβonsetX
P (death) = eβdeathX
1 + eβdeathX
where βonset and βdeath are 1 × 23 column vectors containing the betas for transition to
functional limitation and death respectively, shown in Table 1 (see p 7). X is a matrix
containing the prevalence of chronic conditions and sociodemographic variables by two-
year age group at time t.
TABLE 2: COMPARISON OF POPULATION PROJECTION FROM SIMULATED POPULATION
WITH GOVERNMENT ACTUARY DEPARTMENT PROJECTIONS
Population (thousands)
2005 2015 2025
Simulated population 8,457.4 10,202.5 11,960.6
2002-based principal GAD projection 8,586.1 10,349.9 12,132.4
2003-based principal GAD projection 8,585.0 10,313.2 12,098.3
2004-based principal GAD projection 8,585.6 10,311.1 12,119.9
LITERATURE REVIEW 9
Methods
The purpose of the review was to address two questions for each of the three diseases.
1. What are the trends in disease prevalence and disease-specific disability (where
known) from 1990 to 2005, and how are these projected to develop to 2031:
– in those aged 65 years and over?
– in those aged 40 and over who will be aged 65+ years by 2031?
2. What are the new therapies that may impact on disease prevalence and disease-
specific disability up to 2031, and what evidence is there for efficacy, cost-effectiveness
and diffusion?
Within the models it was possible to adjust three quantities for each disease – the
prevalence, the probability of death within a two-year time window, and the probability of
becoming disabled within two years – the last two quantities being functions of βonset and
βdeath as shown in the box opposite. The literature review allowed us to weigh evidence on
risk factors, preventive strategies and treatments to guide the amount by which these
three quantities might change.
We confined the final choice of literature to:
 important risk factors with established trends, where there is good evidence:
– that the factor is associated with disease, disability or survival with disease
– on risk factor trends
– that the factor is applicable to a sufficiently large section of the population to
estimate a significant impact over the period 2005–31 
 potentially effective preventive strategies and treatments with good evidence:
– that the preventive factor has beneficial effect on disease incidence, disease-
specific disability or survival with disease
– that the factor is newly applicable to a sufficiently large section of the population
to estimate a significant impact over the period 2005–31. ‘Applicable’ takes into
account at-risk population, cost and feasibility.
Two separate searches were undertaken, with additional information from the websites of
the National Institute for Health and Clinical Excellence (NICE), the National Service
Frameworks and the National Sentinel Audits.
 Medline, Embase and HIMIC and ASSIA were searched for articles on trends in disease
published since 2000. The search terms used were trends, futurology, advances,
future, twenty-first century and epidemiology. Results were hand searched to identify
publications on trends in prevalence, incidence and disease-specific mortality and
disability, and new developments in treatment.
 Medline, Embase, Cochrane and DARE (the Database of Abstracts of Reviews of
Effects held by the Cochrane collaboration at the University of York) were searched
Literature review
for reviews published since 1990, to capture evidence for new therapeutic
interventions.
We summarise the literature reviews in each disease area below but fuller details are
available (see www.hs.le.ac.uk/nccsu).
Results
Dementia and cognitive impairment
The box below summarises the results of the literature review for dementia and cognitive
impairment. The main finding was that there was no evidence for increasing or decreasing
incidence other than might occur through the increase or decrease in cerebrovascular risk
factors and treatment. 
Most of the literature on the effect of treatments or interventions reported change in
cognition with no good numerical data on the impact on daily living or disability.
Stroke
The results of the literature review for stroke are summarised in the box opposite. The main
findings are the continued decreases in stroke mortality with a similar pattern to coronary
heart disease (CHD), suggesting shared risk factors, and the potential for reductions in
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SUMMARY OF FINDINGS FROM LITERATURE REVIEW FOR DEMENTIA
 Increasing age is the most important risk factor for dementia and in an ageing
population will make the greatest contribution to increasing the costs of care.
 An American model predicts a three- to fourfold increase in prevalence of Alzheimer’s
disease (AD) between 2000 and 2050 without any change in incidence and
progression.
 Incidence rates rise exponentially with age, but sex differences in incidence are small,
although women may survive longer with AD.
 Evidence on trends is limited, but what there is suggests that incidence is stable.
 The only major established risk factors are cerebrovascular, associated with steeper
decline in AD as well as onset of vascular dementia.
 Cholinesterase inhibitors may have a material effect on disease-specific disability
rates, but their continued inclusion in NICE guidelines remains in doubt. Service
developments to facilitate early diagnosis and drug treatment may themselves have a
positive effect on reducing disability.
 Non-steroidal anti-inflammatory drugs (NSAIDs) may offer some protection against
AD.
 There is limited evidence for the benefit of other drugs, but long-term effect, safety
and cost-effectiveness remain to be established.
 Systematic reviews of non-pharmacological interventions are mostly inconclusive,
based on very few good quality studies. However, there is limited evidence for
effectiveness of preventive home visits, and of snoezelen, an indoor controlled multi-
sensory environment to provide comfort.
stroke incidence and recurrence with good control of vascular risk factors such as
hypertension. 
Most of the literature on the effect of treatments or interventions reported dependency and
death as a joint outcome, providing little firm conclusions on how treatments might impact
on disability.
Coronary heart disease
The results of the literature review for CHD are summarised in the box overleaf. The main
findings are the continued decreases in mortality, an apparent reduction in risk factors
particularly among obese individuals, and evidence that effective treatments are not
reaching certain subgroups of the population, particularly women and older people.
All of the literature on the effect of treatments or interventions reported mortality as the
outcome and provided no data on how treatments might impact on disability. 
Arthritis
The results of the literature review for arthritis are summarised in the box overleaf.
Although the literature for both rheumatoid arthritis and osteoarthritis were reviewed, we
considered only osteoarthritis for the purposes of our simulation model because this is the
major cause of disability from arthritis at older ages. 
The main findings are the lack of data on trends in either incidence or prevalence,
although there is some evidence that the impact of rising obesity levels will contribute to
an increase in both the incidence and the disabling effects. There was little evidence for
the efficacy of treatments.
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SUMMARY OF FINDINGS FROM LITERATURE REVIEW FOR STROKE
 Prevalence of cerebrovascular disease (CVD) rises exponentially with age. Stroke
mortality is declining.
 Trends in mortality from ischaemic stroke (cerebral infarct) and CHD are similar,
suggesting shared risk factors.
 There is good evidence for the effectiveness of statins to reduce the risk of stroke in
secondary prevention.
 There is evidence for the use of oral anticoagulants in primary prevention in those
with non-valvular atrial fibrillation.
 There is evidence for efficacy of treatments for hypertension on primary prevention of
stroke and for secondary prevention with reduction in stroke recurrence.
 There is evidence for the effect of aspirin for primary prevention of myocardial
infarction (MI), and ischaemic stroke at a cost of increased risk of haemorrhagic
stroke and for secondary prevention in acute ischaemic stroke.
 There is evidence for an effect of rehabilitation (stroke units, therapy-based
rehabilitation) on death and dependency after a stroke.
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SUMMARY OF FINDINGS FROM LITERATURE REVIEW FOR CHD
 Data are not perfect, but suggest decreasing incidence of CHD during the 1980s and
1990s, accompanied by earlier diagnosis.
 Case fatality has decreased for MI, and this will contribute to increased incidence of
heart failure, although data in England and Wales are sketchy.
 Declines in CHD may be less in women, but data are lacking.
 Declines in CHD in ‘white’ men may be counterbalanced by substitution of higher
rates for men of south Asian ethnicity, but data are lacking.
 Evidence of reduction of risk factors over time, particularly in obese individuals, so
there may be a lower impact of rising trends in obesity than previously thought.
 Continued refinement of endovascular and surgical treatments for acute coronary
syndrome, and improved risk stratification, will reduce incidence of disability,
perhaps with greater gains possible in women.
 Evidence that effective treatments are not reaching women and older patients.
SUMMARY OF FINDINGS FROM LITERATURE REVIEW FOR OSTEOARTHRITIS
 Osteoarthritis (OA) is associated with more limitations in activities of daily living
among older people than any other disease.
 Evidence for trends in the prevalence and incidence of OA is lacking.
 Age is the strongest predictor of OA and the total number of people with OA will
continue to rise as a result of increasing life expectancy.
 Before age 50, the prevalence of OA is higher in men than in women for most joints.
After age 50, women are more likely to have hand, foot and knee arthritis than men.
 The role of oestrogens in causing OA is unclear but likely to be complex: osteoporosis
appears to protect against the development of OA but exogenous oestrogens may
protect against the progression of established OA.
 There is much evidence for an association with occupational exposure, and evidence
for an association with strenuous sporting activities
 More recently, studies have proved that being overweight is a risk factor for the
development of OA pathology, and for the development of pain and disability in the
presence of pathological changes.
 There is some evidence that exercise in OA patients may have a beneficial effect on
disability.
 There is limited evidence for physiotherapy interventions in reducing the impact of OA
on activities of daily living.
 There is conflicting evidence on the effect of chondroitin sulphate and glucosamine
on OA. Although introduced because of a putative effect on the OA disease process,
their effect, if any, appears to be mostly on the symptoms of pain and disability.
 Viscosupplementation with hyaluronan/hylan has beneficial effects on pain, function
and patient global assessment.
 Acetaminophen (paracetamol) was less effective overall than NSAIDs in terms of pain
reduction and global assessments but both drugs had similar efficacy in terms of
improvements in functional status.
 There is no evidence that currently available NSAIDs affect the disease process in OA,
but the evidence that does exist for their benefit suggests that it is restricted to
symptomatic benefits on pain and improved function.
Even though arthritis is disabling rather than fatal, we did not find a consensus on
outcome measures that reflected daily life functioning, although there are moves to
address this. 
There are two separate but related targets for prevention and treatment: the underlying
pathology of the bone and joint (the disease of OA), and the pain and disability associated
with the pathology. Apart from joint replacements for those with advanced disease, there
is little evidence for the efficacy of treatments for the disease process, although obesity
control, physical fitness and reduced occupational stresses on joints should all
theoretically reduce incidence or slow progression. Most other interventions are directed
at reducing the impact of the disease by symptomatic treatments of pain and disability or
by environmental adaptations. 
The efforts of pharmaceutical companies include a focus on identifying ways to affect the
early triggers of the OA process and on treatments that protect cartilage from degradation
or the bone from micro-trauma. It seems plausible to include, as one potential albeit very
speculative scenario, the possibility of a new development in this field.
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The future numbers of older people with significant disability will depend on the disabling
diseases from which they suffer and whether optimal treatments to alleviate or postpone
the disablement are both available and widely spread throughout the population in need.
As well as considering individual scenarios for the specific diseases – dementia, arthritis,
stroke and coronary heart disease (CHD) – we built three combined scenarios based on
the literature reviews. These are summarised in the box below. 
The rationale underlying each of the individual disease scenarios and the combined
scenarios are detailed below in terms of the changes to the three quantities in the model:
the prevalence of the disease, the probability of disease-specific disability onset in terms
of βonset and the probability of disease-specific death in terms of βdeath. 
It is assumed that if there is no change in the duration with disease then a change in
incidence can be modelled as a change in prevalence.
Scenarios
SUMMARY OF MAIN SCENARIOS
No change: the age-specific prevalence of diseases remains the same, with prevention
strategies and effective treatments simply offsetting the negative influences of obesity
and other cohort trends that increase the prevalence of stroke and CHD. Incidence of and
recovery rates from dependency remain the same with no further effect of treatments.
Mortality rates continue to decline at levels commensurate with Government Actuary’s
Department (GAD) principal projections.
Poorer population health: obesity trends of an annual 2 per cent increase continue. This
increases the prevalence of arthritis, stroke, CHD and vascular dementia, but in addition
the consequent dependency associated with these diseases. The emergence of ethnic
minorities in significant numbers into the older population adds to the prevalence of
stroke and CHD. Some prevention strategies are in place but they fail to offset the
increasing prevalence. Treatments continue to focus on reducing the mortality from
diseases rather than reducing the disabling effects.
Improving population health: individuals are taking their health seriously and there is a
decline in risk factors, particularly smoking and obesity. The health service is responsive
with high rates of technology uptake for disease prevention and excellent rates of spread
of treatments to all who can benefit, particularly in terms of control of vascular risk
factors.
Given the paucity of data on the impact of interventions on disability in any of the disease
areas, we assumed a change of 5 per cent in either βonset or βdeath to represent a small
impact and a change of 10 per cent to represent a moderate impact.
Dementia
Mild cognitive impairment and moderate or worse cognitive impairment were modelled as
separate factors in the transition phase. In the scenarios these are generally grouped
together as dementia. The scenarios are built around assumptions about a reduction in
the incidence of dementia, improvements in survival in those with dementia and a
reduction in the disabling consequences of dementia.
Scenario 1 
Reductions in the incidence of dementia of 10 per cent (scenario 1a), 25 per cent (scenario
1b) and 50 per cent (scenario 1c) from 2011 reflect assumptions of delayed onset
(Brookmeyer et al 1998) or better control of hypertension, possibly reducing incidence by
up to 50 per cent (Forette et al 1998). To simulate delayed onset, the model assumes a
reduction in the prevalence of dementia by 2 per cent, 5 per cent and 13 per cent of the
previous level every 2 years, from 2011, for mild cognitive impairment (Mini-Mental State
Examination [MMSE] score of 22–25) and, from 2015, for moderate or severe dementia
(MMSE score of ≤ 21).
Scenario 2 
This is an improvement in the length of survival with dementia, in line with the control of
vascular risk factors in those with mild cognitive impairment. As mortality is reduced in the
model year on year, as for the GAD projections, it is assumed that only a small further
reduction would take place and only in those with mild dementia. Thus, this scenario
results from a reduction in the transition from mild cognitive impairment to death (βdeath)
of 5 per cent from 2015.
Scenario 3 
This is a reduction in the disabling effect of dementia. It has been reported that
cholinesterase inhibitors could delay the time to evident functional decline by between six
months and a year (Wolfson et al 2002; Feldman et al 2005). Although this is not presently
viewed as a cost-effective treatment (Loveman et al 2005), the patent on donepezil will
expire in 2010 and the treatment should then be widely available at a lower cost. This
scenario is modelled by a 10 per cent reduction in the transitions to disability (βdisability) in
those with mild cognitive impairment from 2011. 
Scenario 4 
This is a composite scenario of the previous ones that is a more realistic scenario for
optimum control of vascular risk factors, with not only improved survival of those with
dementia (scenario 2) and a delay in the onset of dementia (scenario 1) in those with
vascular disease (Feigin et al 2005), but also delayed functional loss (scenario 3; DiCarli
2003). 
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Arthritis
Evidence for trends in the prevalence and incidence of OA is lacking, but recently studies
have demonstrated the role of obesity as a risk factor for the development of OA with, for
instance, one-third of knee OA being attributable to obesity (Felson et al 2000). There is no
good evidence for an effective treatment for OA but weight reduction does appear to have
a positive effect on it (Felson et al 1992). Hence scenarios were linked through to
assumptions about future trends in obesity.
Scenario 1 
This is an increase in the prevalence of arthritis on the basis that obesity has contributed
to around 20 per cent of arthritis (Leveille et al 2005), obesity doubles the risk of disability
in those with arthritis (Okoro et al 2004) and obesity prevalence has increased by around 2
per cent a year over the last decade (Health Survey for England 2003). This is modelled as
an increase in the prevalence of arthritis by 2 per cent every 10 years or 0.5 per cent every 2
years from 2001, and an increase in the transition to disability in those with arthritis
(βdisability) by 10 per cent from 2001.
Scenario 2 
This is a reduction in the levels of obesity in line with improved health behaviours, with a
positive impact on the prevalence of arthritis and its disabling effects. It is assumed that
this would take some time to take effect at a population level. This is modelled as a
reduction in the prevalence of arthritis of 2 per cent every 2 years from 2011 and a
reduction in the transition to disability (βdisability) by 10 per cent from 2011. 
Stroke and coronary heart disease
Stroke and CHD are considered jointly, as trends in mortality from ischaemic stroke and
CHD are similar, suggesting shared risk factors, and many drug treatments are effective in
both. The scenarios were built around assumptions of continuing reductions in case
fatality but no reduction in the disabling consequences, a concerted effort to reduce
vascular risk factors and obesity in line with the population being engaged in good health
behaviours, and a continuance of obesity trends in addition to the focus remaining on
reducing mortality rather than reducing the disabling effects of stroke or CHD. 
Scenario 1 
This is further reductions in case fatality from stroke and CHD above and beyond GAD
projections, but no reduction in disabling consequences. This is modelled through a small
further reduction in the stroke and CHD disease-specific transition to death (βdeath) by 5
per cent from 2015. 
Scenario 2 
This is reduction in stroke and CHD risk, recurrent stroke (a marker for disability) and
mortality through intensive hypertension control. The strength of obesity as a risk factor for
CHD (and stroke) suggests that reducing the levels of obesity would have a positive impact
on the incidence (and therefore the prevalence) of CHD and stroke, and on their disabling
consequences, through reductions in recurrent stroke. This is modelled as a reduction in
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the prevalence of stroke and CHD by 2 per cent per year from 2011, together with a
moderate reduction in the transition to disability (βdisability) by 10 per cent from 2011, and a
small further (over and above that included in the GAD projections) reduction in disease-
specific mortality (βdeath) by 5 per cent from 2015. 
Scenario 3 
This is increases in the prevalence of stroke and CHD, in line with rising levels of obesity;
decreasing mortality from stroke and CHD remains the focus for treatments, with a
consequent further small reduction in mortality evident by 2015, but a rise in the disabling
consequences. This is modelled as an increase in the prevalence of both stroke and CHD
by 0.5 per cent per year from 2001, together with a moderate increase in the transition to
disability (βdisability) by 10 per cent from 2001 and a further small reduction in disease-
specific mortality (βdeath) by 5 per cent from 2015.
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No-change scenario
Between 2005 and 2025 the population aged 65 years and over will increase by 41 per cent
from 8,457,000 to 11,961,000. The largest growth in the older population will be in those
aged 85 years and over, with numbers rising by 87 per cent (Table 3). 
As a result of the continued ageing of the older population, the numbers with disability will
increase by 67 per cent from 868,000 to 1,446,000. The majority of these will be in the
oldest age groups, the numbers of those aged 85 years and over with disability more than
doubling in the next 20 years.
Results
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TABLE 3: SIMULATED TOTAL AND DISABLED POPULATIONS BY AGE UNDER THE
ASSUMPTION OF NO CHANGE IN AGE-SPECIFIC PREVALENCE OF DISEASE, INCIDENCE
AND RECOVERY RATES TO DISABILITY, AND MORTALITY RATES CONTINUING TO
DECLINE AT LEVELS COMMENSURATE WITH GAD PRINCIPAL PROJECTIONS
Population (thousands)
2005 2011 2015 2021 2025
65–74 years
Total population 4,403 4,854 5,519 5,799 5,803
Disabled population 195 217 246 269 264
% disabled 4.43 4.46 4.45 4.64 4.55
75–84 years
Total population 3,048 3,074 3,247 3,712 4,276
Disabled population 324 332 355 408 464
% disabled 10.64 10.81 10.92 10.98 10.86
85+ years
Total population 1,006 1,290 1,437 1,693 1,881
Disabled population 348 455 524 640 717
% disabled 34.62 35.30 36.49 37.78 38.13
All 65+ years
Total population 8,457 9,217 10,202 11,205 11,961
Disabled population 868 1,004 1,125 1,316 1,446
% disabled 10.26 10.90 11.02 11.75 12.09
By 2025 the proportion of the older population with disability will have risen by 2 per cent
to 12.1 per cent.
Under the no-change scenario, the number of people aged 65 years and over who have
experienced a stroke would increase by 46 per cent, from 601,000 in 2005 to 878,000 in
2025 (see Table 4 below). Over the same period, the numbers with coronary heart disease
(CHD) would increase by 42 per cent (from 1,808,000 to 2,566,000), the number with
arthritis would increase by 42 per cent (from 4,354,000 to 6,194,000) and the numbers with
mild cognitive impairment would increase by 43 per cent (from 1,807,000 to 2,591,000).
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TABLE 4: SIMULATED PREVALENCE OF DISEASE BY AGE UNDER THE ASSUMPTION OF NO
CHANGE IN AGE-SPECIFIC PREVALENCE OF DISEASE, INCIDENCE AND RECOVERY RATES
TO DISABILITY, AND MORTALITY RATES CONTINUING TO DECLINE AT LEVELS
COMMENSURATE WITH GAD PRINCIPAL PROJECTIONS
Percentage of disease prevalence (thousands)
2005 2011 2015 2021 2025
Stroke
65–74 years 5.4 (238) 5.4 (262) 5.4 (297) 5.5 (317) 5.4 (315)
75–84 years 8.8 (268) 8.8 (272) 8.9 (287) 8.9 (329) 8.8 (378)
85+ years 9.5 (95) 9.6 (123) 9.7 (139) 9.8 (166) 9.9 (185)
Total 7.1 (601) 7.1 (657) 7.1 (724) 7.3 (812) 7.3 (878)
Coronary heart disease
65–74 years 19.9 (877) 19.9 (965) 19.8 (1,095) 20.0 (1,162) 19.9 (1,156)
75–84 years 23.3 (709) 23.3 (715) 23.3 (755) 23.3 (864) 23.3 (994)
85+ years 22.1 (222) 22.1 (285) 22.1 (318) 22.1 (374) 22.1 (416)
Total 21.4 (1,808) 21.3 (1,965) 21.3 (2,168) 21.4 (2,399) 21.5 (2,566)
Arthritis
65–74 years 48.1 (2,116) 48.0 (2,330) 48.0 (2,647) 48.2 (2,795) 48.1 (2,789)
75–84 years 55.0 (1,677) 55.0 (1,691) 55.0 (1,786) 55.0 (2,042) 55.0 (2,350)
85+ years 55.8 (561) 55.8 (720) 55.9 (804) 56.0 (948) 56.0 (1,054)
Total 51.5 (4,354) 51.4 (4,741) 51.3 (5,237) 51.6 (5,785) 51.8 (6,194)
Mild cognitive 
impairment
65–74 years 15.4 (676) 15.3 (742) 15.2 (841) 15.5 (901) 15.4 (892)
75–84 years 27.7 (844) 27.7 (850) 27.6 (896) 27.5 (1,022) 27.4 (1,174)
85+ years 28.5 (286) 28.4 (366) 28.2 (405) 28.0 (474) 28.0 (526)
Total 21.4 (1,807) 21.3 (1,959) 21.0 (2,142) 21.4 (2,397) 21.7 (2,591)
Moderate cognitive
impairment
65–74 years 3.1 (136) 3.1 (150) 3.1 (170) 3.2 (184) 3.1 (181)
75–84 years 10.7 (326) 10.7 (330) 10.7 (348) 10.7 (396) 10.6 (451)
85+ years 36.2 (364) 36.5 (471) 36.9 (531) 37.4 (634) 37.6 (707)
Total 9.8 (827) 10.3 (950) 10.3 (1,048) 10.8 (1,214) 11.2 (1,339)
Poorer population health
Under the assumption of poorer population health, increases in the size of the older
population overall and within age groups are similar to those for the no-change scenario.
However, the numbers with disability increase by 69 per cent to 1,504,000 by 2025 and the
numbers aged 85 years and over with disability more than double (see Table 5 below).
Thus poorer population health results in greater numbers with disability compared with
the no-change scenario (see Figure 2 opposite).
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TABLE 5: SIMULATED TOTAL AND DISABLED POPULATIONS BY AGE UNDER THE
ASSUMPTION OF POORER POPULATION HEALTH*
Population (thousands)
2005 2011 2015 2021 2025
65–74 years
Total population 4,402 4,852 5,517 5,801 5,805
Disabled population 199 222 252 277 273
% disabled 4.52 4.57 4.57 4.78 4.70
75–84 years
Total population 3,047 3,069 3,239 3,713 4,281
Disabled population 334 345 370 428 490
% disabled 10.95 11.25 11.41 11.51 11.43
85+ years
Total population 1,005 1,287 1,425 1,689 1,880
Disabled population 356 467 538 659 742
% disabled 35.41 36.42 37.74 39.01 39.47
All 65+ years
Total population 8,454 9,203 10,181 11,203 11,965
Disabled population 888 1,034 1,160 1,364 1,504
% disabled 10.51 11.24 11.39 12.17 12.57
* Poorer population health: prevalence of arthritis, stroke and coronary heart disease increases by 0.5 per cent every two years
from 2001, transition rates to disability increase by 10 per cent for arthritis, stroke and coronary heart disease from 2001, and
mortality rates from disability decrease by 5 per cent for mild dementia, stroke and coronary heart disease from 2015.
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CHANGE IN NUMBERS WITH DISEASE UNDER SCENARIO OF POORER POPULATION HEALTH COMPARED
WITH THE NO-CHANGE SCENARIO (AGEING OF POPULATION ONLY), 2001 TO 2025
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CHANGE IN NUMBERS OF DISABLED OLDER PEOPLE UNDER SCENARIO OF POORER POPULATION HEALTH
COMPARED WITH THE NO-CHANGE SCENARIO, 2001 TO 2025
2
70
60
50
40
30
20
10
0
N
um
be
r o
f d
is
ab
le
d 
ol
de
r p
eo
pl
e 
(t
ho
us
an
ds
)
2001 2003 2005 2007 2009 2011 2013 2015 2017 2019 2021 2023 2025
Year
KEY
65–74 years
75–84 years
85+ years
Total
The numbers with disease increase slightly compared with the scenario of no change (see
Figure 3, p 21). The highest increase is in the numbers with moderate or severe cognitive
impairment, with a rise of 20,000 compared with the no-change scenario.
Improving population health
Under the assumption of improving population health, the size of the older population as
a whole will increase by 44 per cent to 12,168,000, whereas that of those aged 85 years
and over will almost double, reaching 1,996,000 by 2025. 
The numbers with disability will continue to grow as the population ages (see Table 6
opposite), but by less than the other two scenarios, the percentage increase being 57 per
cent between 2005 and 2025 (see Figure 4 below). By 2025 the proportion of the older
population with disability will be 11.2 per cent, a rise of around 1 per cent over 20 years.
Again the largest increases in both the numbers and the proportion with disability will be
in those aged 85 years and over; by 2025 687,000 people in this age group will have
disability, an increase of 97 per cent from 2005.
Although improving population health will reduce the numbers with disease, these will
not, apart from stroke, offset the increases resulting from the ageing of the population (see
Figure 5 opposite). The number of people with arthritis will increase the most, with
102,000 more by 2025 compared with the scenario of no change. 
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CHANGE IN NUMBERS OF DISABLED OLDER PEOPLE UNDER SCENARIO OF IMPROVING POPULATION
HEALTH COMPARED WITH THE NO-CHANGE SCENARIO, 2001 TO 2025
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TABLE 6: SIMULATED TOTAL AND DISABLED POPULATIONS BY AGE UNDER THE
ASSUMPTION OF IMPROVING POPULATION HEALTH*
Population (thousands)
2005 2011 2015 2021 2025
65–74 years
Total population 4,403 4,854 5,521 5,814 5,821
Disabled population 195 217 239 257 251
% disabled 4.43 4.46 4.33 4.43 4.32
75–84 years
Total population 3,048 3,074 3,252 3,754 4,352
Disabled population 324 332 339 380 428
% disabled 10.64 10.81 10.44 10.12 9.83
85+ years
Total population 1,006 1,290 1,444 1,753 1,996
Disabled population 348 455 507 611 687
% disabled 34.62 35.30 35.11 34.84 34.40
All 65+ years
Total population 8,457 9,217 10,217 11,322 12,168
Disabled population 868 1,004 1,086 1,248 1,366
% disabled 10.26 10.90 10.62 11.02 11.22
* Improving population health: prevalence of arthritis, stroke, coronary heart disease and mild dementia decreases by 2 per cent
every two years from 2011, moderate dementia decreases by 2 per cent every two years from 2015, transition rates to disability
decrease by 10 per cent for arthritis, stroke, coronary heart disease and mild dementia from 2011, and mortality rates from
disability decrease by 5 per cent for mild dementia, stroke and coronary heart disease from 2015.
CHANGE IN NUMBERS WITH DISEASE UNDER SCENARIO OF IMPROVING POPULATION HEALTH COMPARED
WITH THE NO-CHANGE SCENARIO (AGEING OF POPULATION ONLY), 2001 TO 2025
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Dementia
Decreasing the prevalence of dementia by just 2 per cent would decrease the size of the
disabled population by 11,000 compared with the assumption of no change, and increase
the total population by 100,000 by 2025. The proportion of the population aged 65 and
over with disability would thus reduce slightly. If the prevalence were decreased by 13 per
cent, the disabled population would decrease by 60,000 by 2025, compared with the
assumption of no change, and the total population would increase by 450,000, resulting in
a 1 per cent decrease in the proportion of the total population with disability.
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CHANGE IN TOTAL NUMBERS OF OLDER PEOPLE UNDER SCENARIOS OF DIFFERING DEMENTIA TRENDS
COMPARED WITH THE NO-CHANGE SCENARIO (AGEING OF POPULATION ONLY), 2001 TO 2025
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Scenario 1a: Mild cognitive impairment decreased by 2% every 2 years from 2011, moderate cognitive 
impairment decreased by 2% every 2 years from 2015
Scenario 1b: Mild cognitive impairment decreased by 5% every 2 years from 2011, moderate cognitive 
impairment decreased by 5% from 2015
Scenario 1c: Mild cognitive impairment decreased by 13% every 2 years from 2011, moderate cognitive 
impairment decreased by 13% from 2015
Scenario 2: Transition rate to death decreased by 5% from 2015 for mild cognitive impairment
Scenario 3: Transition rate to disability decreased by 10% from 2011 for mild cognitive impairment
Scenario 4: Prevalence of mild cognitive impairment decreased by 2% every 2 years from 2011, moderate 
cognitive impairment decreased by 2% every 2 years from 2015; transition rate to disability decreased by 10%
from 2011 and to death decreased by 5% from 2015 for mild cognitive impairment only
Increasing the survival of those with dementia would lead to an increase of 25,000 in the
total population by 2025 compared with the assumption of no change, with a
corresponding increase in the size of the dependent population, implying that those who
would live longer would live with disability.
Reducing the disabling consequences of dementia would lead to a decrease in the size of
the dependent population, but little change in the total population, so the proportion with
disability would decrease slightly.
For scenario 4, where it is assumed that the UK experiences delayed onset of dementia in
those with vascular disease, improved survival with dementia, as well as delayed
functional loss, there would be an increase in the total population of 119,000 by 2025
compared with assuming no change, and a decrease in the disabled population of 19,000.
Thus the proportion with disability would decrease by 0.4 per cent.
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CHANGE IN NUMBERS OF DISABLED OLDER PEOPLE UNDER SCENARIOS OF DIFFERING DEMENTIA TRENDS
COMPARED WITH THE NO-CHANGE SCENARIO (AGEING OF POPULATION ONLY), 2001 TO 2025
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Scenario 1a: Mild cognitive impairment decreased by 2% every 2 years from 2011, moderate cognitive 
impairment decreased by 2% every 2 years from 2015
Scenario 1b: Mild cognitive impairment decreased by 5% every 2 years from 2011, moderate cognitive 
impairment decreased by 5% from 2015
Scenario 1c: Mild cognitive impairment decreased by 13% every 2 years from 2011, moderate cognitive 
impairment decreased by 13% from 2015
Scenario 2: Transition rate to death decreased by 5% from 2015 for mild cognitive impairment
Scenario 3: Transition rate to disability decreased by 10% from 2011 for mild cognitive impairment
Scenario 4: Prevalence of mild cognitive impairment decreased by 2% every 2 years from 2011, moderate 
cognitive impairment decreased by 2% every 2 years from 2015; transition rate to disability decreased by 10%
from 2011 and to death decreased by 5% from 2015 for mild cognitive impairment only
The effect of the different dementia scenarios on the size of the older population in total as
well as the numbers with disability, over and above that caused by the ageing of the
population, are shown in Figure 6 (see p 24) and Figure 7 (see p 25).
Arthritis
Increasing the prevalence of arthritis by 0.5 per cent as well as the disabling consequences
would lead to a rise of 39,000 in the dependent population by 2025, over and above the
increases caused by ageing of the population (see Figure 8 below), with the greatest
difference being seen in those aged 75 years and over.
Decreasing the prevalence of arthritis by 2 per cent, and reducing the disabling
consequences, would lead to a decrease of 50,000 in the numbers disabled by 2025,
resulting in a 0.4 per cent decrease in the proportion of the population with disability
compared with no change (see Figure 8 above). This difference in the proportion with
disability would be greatest for those aged 85 years and over.
26 COMPRESSION OR EXPANSION OF DISABILITY?
CHANGE IN NUMBERS OF DISABLED OLDER PEOPLE UNDER SCENARIOS OF DIFFERING ARTHRITIS TRENDS
COMPARED WITH THE NO-CHANGE SCENARIO (AGEING OF POPULATION ONLY), 2001 TO 2025
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Scenario 1: Prevalence increased by 0.5% every 2 years from 2001; transition rate to disability increased by 10% 
from 2001
Scenario 2: Prevalence increased by 2% every 2 years from 2011; transition rate to disability decreased by 10% 
from 2011
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TABLE 7: SIMULATED TOTAL AND DISABLED POPULATIONS BY AGE GROUP FOR
ARTHRITIS SCENARIO 1* 
Population (thousands)
2005 2011 2015 2021 2025
65–74 years
Total population 4,403 4,853 5,519 5,799 5,803
Disabled population 198 220 251 275 270
% disabled 4.49 4.54 4.54 4.74 4.66
75–84 years
Total population 3,048 3,072 3,245 3,710 4,274
Disabled population 331 341 365 421 48
% disabled 10.85 11.11 11.25 11.36 11.26
85+ years
Total population 1,005 1,287 1,432 1,687 1,874
Disabled population 354 464 535 653 733
% disabled 35.16 36.05 37.32 38.71 39.13
All 65+ years
Total population 8,456 9,212 10,196 11,196 11,951
Disabled population 882 1,026 1,150 1,349 1,485
% disabled 10.43 11.13 11.28 12.05 12.42
* Arthritis scenario 1: prevalence increases by 0.5 per cent every 2 years from 2001, and transition rates from independent to
disabled increase by 10 per cent from 2001. 
TABLE 8: SIMULATED TOTAL AND DISABLED POPULATIONS BY AGE GROUP FOR
ARTHRITIS SCENARIO 2* 
Population (thousands)
2005 2011 2015 2021 2025
65–74 years
Total population 4,403 4,854 5,519 5,799 5,802
Disabled population 195 217 242 262 256
% disabled 4.43 4.46 4.38 4.52 4.42
75–84 years
Total population 3,048 3,074 3,247 3,713 4,277
Disabled population 324 332 347 393 444
% disabled 10.64 10.81 10.68 10.57 10.38
85+ years
Total population 1,006 1,290 1,437 1,696 1,886
Disabled population 348 455 516 623 696
% disabled 34.62 35.30 35.89 36.75 36.90
All 65+ years
Total population 8,457 9,217 10,203 11,208 11,966
Disabled population 868 1,004 1,104 1,278 1,396
% disabled 10.26 10.90 10.82 11.40 11.67
* Arthritis scenario 2: prevalence reduces by 2 per cent every 2 years from 2011, and transition rates from independent to disabled
reduce by 10 per cent from 2011. 
Stroke and coronary heart disease
A further decrease in the case fatality for stroke or CHD would increase the total population
by 25,000 by 2025, over and above that caused by the ageing of the population (see Figure
9 opposite). The disabled population would, however, also rise, although the proportion
with disability would rise only slightly (see Table 10 below, and Figure 10, p 30).
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TABLE 9: SIMULATED TOTAL AND DISABLED POPULATIONS FOR DIFFERING SCENARIOS
OF STROKE AND CORONARY HEART DISEASE TRENDS
Population (thousands)
2005 2011 2015 2021 2025
Scenario 11
Total population 8,457 9,217 10,202 11,221 11,986
Disabled population 868 1,004 1,125 1,318 1,449
% disabled 10.26 10.90 11.02 11.74 12.09
Scenario 22
Total population 8,457 9,217 10,209 11,253 12,042
Disabled population 868 1,004 1,116 1,304 1,434
% disabled 10.26 10.90 10.93 11.59 11.91
1 Transition from independent to death decreases by 5 per cent for stroke and coronary heart disease from 2015.
2 Prevalence decreases by 2 per cent per year from 2011, transition rates from independent to disabled decrease by 10 per cent
from 2011, and transition rates from independent to death decrease by 5 per cent from 2015.
TABLE 10: SIMULATED TOTAL AND DISABLED POPULATIONS BY AGE GROUP FOR
STROKE AND CORONARY HEART DISEASE SCENARIO 3*
Population (thousands)
2005 2011 2015 2021 2025
65–74 years
Total population 4,403 4,852 5,517 5,799 5,802
Disabled population 196 218 248 271 266
% disabled 4.46 4.49 4.49 4.68 4.59
75–84 years
Total population 3,048 3,070 3,241 3,709 4,273
Disabled population 327 336 359 413 471
% disabled 10.73 10.95 11.07 11.14 11.03
85+ years
Total population 1,005 1,286 1,430 1,687 1,874
Disabled population 351 459 528 644 723
% disabled 34.87 35.66 36.90 38.17 38.57
All 65+ years
Total population 8,455 9,208 10,188 11,195 11,950
Disabled population 874 1,013 1,134 1,328 1,461
% disabled 10.33 11.00 11.13 11.87 12.22
* Coronary heart disease scenario 3: prevalence increases by 0.5 per cent every 2 years from 2001, transition rates from
independent to disabled increase by 10 per cent from 2011, and transition rates from independent to death decrease by
5 per cent from 2015.
A decrease in the prevalence of stroke and CHD of 2 per cent and in the risk of becoming
disabled of 10 per cent, as well as in the risk of dying of 5 per cent, would lead to a rise in
the total population of 82,000 by 2025 (see Table 9 opposite). The disabled population
would decrease by 11,500 by 2025, over and above that caused by the ageing of the
population (see Table 9 opposite and Figure 10 overleaf).
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CHANGE IN TOTAL NUMBERS OF OLDER PEOPLE UNDER SCENARIOS OF DIFFERING STROKE AND CORONARY
HEART DISEASE TRENDS COMPARED WITH THE NO-CHANGE SCENARIO (AGEING OF POPULATION ONLY), 
2001 TO 2025
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Scenario 1: Transition rate to death decreased by 5% from 2015
Scenario 2: Prevalence decreased by 2% every 2 years from 2011; transition rate to disability decreased by 10% 
from 2011 and to death decreased by 5% from 2015
Scenario 3: Prevalence increased by 0.5% every 2 years from 2001; transition rate to disability increased by
10% from 2001 and to death increased by 5% from 2015
If the prevalence of stroke and CHD increases along with their disabling consequences and
the case fatality decreases, the total older population will increase by 10,000 over and
above the increases caused by population ageing (see Table 10, p 28 and Figure 9
opposite). The dependent population would rise by 15,000, leading to a small increase in
the proportion with disability (see Table 10 and Figure 9).
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CHANGE IN NUMBERS OF DISABLED OLDER PEOPLE UNDER SCENARIOS OF DIFFERING STROKE AND CORONARY
HEART DISEASE TRENDS COMPARED WITH THE NO-CHANGE SCENARIO (AGEING OF POPULATION ONLY), 
2001 TO 2025
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Conclusions
In this report we have explored the effect of different overall health scenarios on the future
numbers of older people with disability at a level needing significant care (unable to put
on shoes or socks, bath or have an all-over wash, or get in and out of bed). These
projections are based on the individual experiences of a nationally representative sample
of people aged 65 years and over as they experience and report disease and subsequent
disability.
Ageing of the population alone, with no alteration in the prevalence of diseases or the age-
specific rates of becoming disabled or recovering, will result in a 67 per cent increase in
the numbers with disability over the next 20 years. Numbers of the oldest old (those aged
85 years and over) with disability will double. In addition the proportion of the older
population experiencing one of the key diseases considered – arthritis, coronary heart
disease (CHD), stroke and dementia – will increase by over 40 per cent by 2025.
If the emphasis of public health interventions and medical treatments continues to be on
extending life at older ages in those with disease, with little or no consideration for the
quality of life in terms of alleviating or postponing the disabling consequences of disease,
there will be a significant increase in the size of the disabled population and an expansion
of disability. By 2025 we estimate that there will be around 50,000 extra older people with
disability at a level needing long-term care, in addition to the rises caused by ageing of the
population.
Moderate improvements in population health from reductions in levels of obesity and
other negative health behaviours and intensive hypertension control could reduce the
prevalence of arthritis, CHD, stroke and dementia. The impact of these, together with the
emergence of new treatments or technologies focused on reducing the disabling
consequences of disease, could considerably reduce the numbers with disability by 2025,
with up to 80,000 fewer disabled older people. However, this will make only limited
inroads into offsetting population ageing and there will still be an overall increase in the
numbers of disabled older people by 57 per cent. Furthermore, any reduction of the
disabling consequences of disease will result in further gains in life expectancy as
mortality rates for non-disabled people are lower than those for disabled people. Thus,
with the exception of stroke, the numbers of those with disease rises, because the overall
reduction of prevalence by 2 per cent every 2 years is insufficient to counteract this
increase. Hence a compression of disability is unlikely unless the level of severity of
disability associated with these diseases diminishes.
Conclusions and
recommendations
Strengths and limitations
The Medical Research Council Cognitive Function and Ageing Study (MRC CFAS) is a
nationally representative longitudinal study of a cohort of older people aged 65 years and
over in 1991. The study included urban and rural areas and those living in institutions and
is therefore representative of the total older population at the beginning of the 1990s.
However, MRC CFAS includes very few older people from ethnic minorities and over the
next 20 years these will form an increasing part of the older population as the large
younger cohorts age. In the 2001 Census only 1 per cent of the older population was of
Asian origin, whereas this rises to 3 per cent for the 40- to 64-year-old age group. We have
not been able explicitly to model the impact of ageing of the ethnic minority populations
because of a lack of data on disability transitions in this population, but the known greater
prevalence of stroke, CHD and diabetes in the south Asian population, the largest ethnic
minority population in the UK, suggests that our estimates may be conservative. 
The majority of projection models have concentrated on a single disease and on its
evolution. Incorporating different diseases with their varied impact on disability and
mortality have enabled the investigation of the impact of treatments such as hypertension
control that reduce mortality in stroke, CHD and vascular dementia, and of risk factors such
as obesity that act concurrently on diseases. Indeed the Second Wanless Report
highlighted obesity as a major public health threat (Wanless 2002). 
Although the diseases considered in the transition model were ascertained from self-
report, the majority were self-reports of doctor-diagnosed morbidity. Moreover, the
prevalence of the main diseases in women aged 70 years and over in MRC CFAS is
commensurate with other British studies, specifically the British Women’s Heart and
Health Study (Adamson et al 2004). The choice of diseases for the transition model was
limited by the study and notably cancer was omitted. However, cancer has consistently
been shown to have the most impact on mortality and little on disability (Mathers 1999).
Limited allowance is made for reductions in mortality from cancer (and other diseases not
included in our model) by the year-on-year gains in survival through the Government
Actuary’s Department (GAD) adjustments. 
Previous projections of the number of older people with disability have relied on cross-
sectional data to estimate the prevalence of disability, with assumptions that the age-
specific prevalence of disability will remain constant over time. Prevalence is a function of
both incidence and duration and therefore may remain constant because incidence and
duration are changing relative to each other. Our projections, on the other hand, use the
incidence of disability and we make the more realistic assumption that age-specific
incidence rates have remained constant from 1991 until 2001. 
Although the temporal relationship between disease and disability is as required, with
disease preceding disability, the specific cause of the subsequent disability was not
ascertained at interview with the older person. Thus the disease–disability link is not
empirically established in our model.
Comparisons with other countries
Comparable projections for the USA deduced that a reduction in the prevalence of arthritis
would have the greatest impact on the prevalence of functional limitations in the older
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population, although the numbers saved from disease would be only a small fraction of
the large population of disabled older people resulting from the ageing of the baby
boomers (Boult et al 1994). However, the Boult model was based on self-report of all
diseases, including memory problems, and only simulated a scenario where prevalence of
each disease was increased by 1 per cent per year. Our findings from SIMPOP are based on
a much greater study size, with objectively measured cognitive impairment and evidence-
based scenarios.
Our findings that continued reductions in mortality at older ages will result in more years
with disability, and potentially greater health care costs, confirm others (Bonneux et al
1998; Wagener et al 2001). In addition, projection models of future numbers with specific
diseases such as dementia (Brookmeyer et al 1998) implicitly echo our findings that the
ageing of the population will result in substantial rises in the numbers of older people with
disability who need social care. 
Evidence for reductions in the levels of disability in the older population worldwide are
varied. Studies from the USA now show clear decreases in the prevalence of disability over
a 20-year period from the beginning of the 1980s, with a more rapid decline in the last
decade. The reasons for this remain unclear, with possible contributors being higher levels
of education, improved medical treatments and greater use of assistive technology that
allows older people to remain independent (Freedman et al 2004). Over a similar time
period the prevalence of severe disability of Spanish older people reduced by over 3 per
cent per year and the disability-free life expectancy (DFLE) increased, although in women
the prevalence of self-care disability increased slightly (Sagardui-Villamor et al 2005).
However, more recently in Sweden the prevalence of objectively measured function
(physical capacity, lung function and cognition) and self-reported diseases increased
between two cohorts who were aged 77 years and over in 1992 and 2002, and this was not
an artefact resulting from omission of those in institutions or a change in reporting or
expectations (Parker et al 2005). Sweden’s life expectancy at birth of 82 years is two years
greater than that of the USA or the UK and one year less than that of Spain. This
demonstrates the variability that exists worldwide on the relationship between longer and
healthier life.
Despite the reports of reductions in disability prevalence, the evidence for how to delay
onset and progression is scant. Our work makes the important link between disease and
disability, suggesting the effect that public health measures for promoting healthy
lifestyles, particularly reducing obesity, might have. Reducing levels of obesity will have
little effect on mortality rates but will have significant impact on disability (Reynolds et al
2005), with obesity in adulthood being associated with double the risk of activities of daily
living (ADL) limitation at older ages (Peeters et al 2004) and showing a greater contribution
to cases of arthritis in more recent years (Leveille et al 2005). Modest reductions in major
cardiovascular risk factors appear more effective in terms of life-years gained than
cardiological treatments (Unal et al 2005), but we need to know whether this is also true
for disability-free life-years.
Recommendations
The planning of preventive, primary and secondary health, social and long-term care
services for older people requires accurate projections of future need based on reliable
estimates of the prevalence and incidence of cognitive and functional impairment. Future
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planning will also require an understanding of the impact of chronic disease on function,
the risk factors for impaired cognition and function, and the changing nature of informal
care and social support, as well as the organisation of formal health, social and long-term
care services, their cost-effectiveness, and the impact of increasing diversity in the older
population resulting from ethnic and generational group differences.
Projections of the numbers and characteristics of the older population directly benefits
health, care and pension providers, and the government, as well as older people
themselves. At present we are limited through a lack of available data on the extent to
which we can incorporate all the likely factors that affect and are affected by increasing
dependency with age. Projections are also limited by the lack of data to inform realistic
future scenarios. Future routine data for public health are unlikely to provide sufficient
data on disability, which necessitates specific dedicated studies for estimating health and
social care costs. 
Projection models that link disease and disability in the manner explored here enable
evidence to be gathered about the potential of treatment and prevention strategies to
reduce the disability burden in the future. It was evident from our thorough and systematic
review of the literature in two of the diseases – stroke and CHD – that the efficacy of
treatments and interventions is mostly assessed in terms of their ability to delay death or a
combination of death and dependency, rather than disability alone. In the other two
diseases – arthritis and dementia – where saving lives is a lesser issue, outcomes were
generally disease-specific measures such as cognitive function scores or physiological
measures. Knowledge of how treatments in these areas improve the ability to function in
daily life activities through the inclusion of these as secondary outcomes would potentially
benefit older people and their families as well as policy-makers. 
Improved treatment and diagnosis will have led to improvements in the health of future
older people, but there are other cohort effects that may result in improvements of similar
magnitude. New cohorts have had the benefit of greater education and better conditions
and nutrition during early life, all of which are known to affect health later in life. It is
important to understand whether socioeconomic differences in the onset of disability are
simply a manifestation of greater disease burden in those with lower socioeconomic
status. However, the true picture of the trends in the health of the UK older population has
been limited by geographical area (Spiers et al 1996) or by exclusion of those in
institutional care (Jarvis 1998). There is only a handful of purposefully designed
longitudinal studies of ageing that have been conducted within the UK, with only the
recent English Longitudinal Study of Ageing (ELSA) and MRC CFAS being nationally
representative. The 15 years that have now elapsed since the MRC CFAS would provide an
ideal opportunity to compare sufficiently different cohorts, but using a large enough
sample to compare down to the level of less prevalent diseases. 
Other groups in which substantial cohort differences may be expected are ageing ethnic
minority populations from Commonwealth countries who migrated to the UK between 1946
and 1965. Individuals in these cohorts are now reaching retirement age and have had very
different life histories and experiences to those expected for subsequent generations.
There is evidence of differences in the prevalence of disease and functioning between
different ethnic groups, but little or none on incidence, and it is unclear whether the health
experience of older people from ethnic minority groups is the result of genetic differences
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or risk factors associated with lifestyle, income and environmental or social deprivation
(Nazroo 1998). The health and morbidity patterns of successive generations of ethnic
minority cohorts could be expected to converge with patterns experienced by the majority
population in the future as differences in socioeconomic status and wealth narrow. The
rate of convergence, however, is not known and therefore baseline data are essential if
these differences are to be investigated in the future. It is essential that such a study
includes objective measures of performance to tease out potential differences in self-rated
disability between ethnic groups and those in institutions, given the variation in
institutionalisation rates between different ethnic groups in the UK.
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